Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer

To study the active targeting efficacy of phenylboronic acid-modified niclosamide solid lipid nanoparticles (PBA-Niclo-SLN) in triple-negative breast cancer (TNBC). PBA-Niclo-SLNs were formulated by an emulsification-solvent evaporation method using PBA-associated stearylamine (PBSA) as lipid. The d...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2020-07, Vol.15 (16), p.1551-1565
Main Authors: SS Pindiprolu, Sai Kiran, Krishnamurthy, Praveen T, Ghanta, Venkata Rao, Chintamaneni, Pavan Kumar
Format: Article
Language:English
Subjects:
Acids
Apoptosis
Bioavailability
Breast cancer
Cell adhesion & migration
Cell cycle
Chemotherapy
Cytotoxicity
Lipids
Medical prognosis
Metastasis
Nanoparticles
niclosamide
Spectrum analysis
STAT3
triple-negative breast cancer
tumor relapse
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the active targeting efficacy of phenylboronic acid-modified niclosamide solid lipid nanoparticles (PBA-Niclo-SLN) in triple-negative breast cancer (TNBC). PBA-Niclo-SLNs were formulated by an emulsification-solvent evaporation method using PBA-associated stearylamine (PBSA) as lipid. The drug uptake and the anticancer propensity of PBA-Niclo-SLN were studied in TNBC (MDA-MB231) cells and tumor-bearing mice. PBA-Niclo-SLN formulation resulted in greater antitumor efficacy by inducing G0/G1 cell cycle arrest and apoptosis. Besides, PBA-Niclo-SLN effectively inhibited STAT3, CD44 /CD24 TNBC stem cell subpopulation, epithelial–mesenchymal transition markers. Besides, PBA-Niclo-SLN selectively accumulated at the tumor site with more significant tumor regression and improved the survivability in TNBC tumor-bearing mice.  PBA-Niclo-SLN formulation would be an effective strategy to eradicate TNBC cells (breast cancer stem cells and nonbreast cancer stem cells) efficiently.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2020-0003